Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction

American Heart Journal

Volumn 137, Issue 4 I, 1999, Pages 646-652

  Senior, R ^a   Basu, S ^a   Kinsey, C ^a   Schaeffer, S ^a   Lahiri, A ^a  

^a ST MARK S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CARVEDILOL; CREATINE KINASE;

ACUTE HEART INFARCTION; ARTICLE; BLOOD CLOT LYSIS; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE MASS; HEART REINFARCTION; HEART VENTRICLE REMODELING; HIGH RISK POPULATION; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

EID: 0032958134     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70217-6     Document Type: Article

References (36)

1. Khattar RS, Basu SK, Raval U, Senior R, Lahiri A. Prognostic value of predischarge exercise testing, ejection fraction and ventricular ectopic activity in acute myocardial infarction treated with streptokinase. Am J Cardiol 1996;78:136-41.
2. Stevenson R, Ranjadayalan K, Wilkinson P, Roberts R, Timmis AD. Short and long prognosis in acute myocardial infarction since introduction of thrombolysis. BMJ 1993;307:349-53.
3. Pfeffer MA, Brawnerald E. Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation 1990;81:1161-72.
4. Ross J Jr. Afterload mismatch and preload reserve: a conceptual framework for the analysis of ventricular function. Prog Cardiovasc Dis 1976;18:255-64.
5. McKay RG, Pfeffer MA, Pasternak RC. Left ventricular remodeling following myocardial infarction: a corollary to infarct expansion. Circulation 1986;74:693-702.
6. Touchstone DA, Beller GA, Nygaard TW, Tedesco C, Kaul S. Effects of successful intravenous perfusion therapy on regional myocardial function and geometry in humans: a tomographic assessment using two dimensional echocardiography. J Am Coll Cardiol 1989;13:1506-13.
7. Litwin SE, Sarah KE, Morgan JP, Douglas PS. Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. Circulation 1994;89:345-54.
8. Ruffolo RR, Gellaim M, Hieble JP, Willete RN, Nicholas AJ. The pharmacology of carvedilol. Eur J Clin Pharmacol 1990;38:82-8.
9. Yue TL, Cheng HY, Lysko PG, Mckenna PJ, Feuerstein R, Gu JL, et al. Carvedilol, a new vasodilator and beta-adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Therap 1992;263:92-8.
10. Sung C-P, Arleth AJ, Ohlstein EH. Carvedilol inhibits vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol 1993; 21:221-7.
11. Ohlstein EH, Douglas SA, Sung CP, Yue TL, Louden C, Arleth A, et al. Carvedilol, a cardiovascular drug prevents vascular smooth muscle cell proliferation, migration and neoimtimal formation following vascular injury. Proc Natl Acad Sci USA 1993;90:6189-93.
12. DasGupta PD, Broadhurst P, Raftery EB, Lahiri A. Value of carvedilol in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990;66:1118-23.
13. DasGupta P, Broadhurst P, Lahiri A. The effects of intravenous carvedilol, a new multiple action vasodilatory b-blocker in congestive heart failure. J Cardiovasc Pharmacol 1991;18(suppl 4):S12-16.
14. Olsen SL. Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure. A double-blind randomized study. J Am Coll Cardiol 1995;25;1225-31.
15. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N England J Med 1996;334:1349-55.
16. Bristow MR, Olsen S, Larrabee P, Gilbert M. The acute effects of carvedilol and metoprolol in patients with dilated cardiomyopathy. J Am Coll Cardiol 1993;21:314A.
17. Feuerstein GZ, Hamburger SA, Smith EF, Bril A, Ruffolo RR. Myocardial protection with Carvedilol. J Cardiovasc Pharmacol 1992;19:S138-41.
18. Basu S, Senior R, Raval U, Van der does R, Bruckner T, Lahiri A. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction: a placebo-controlled, randomized trial. Circulation 1997;96:183-91.
19. Reichek N, Helak J, Plappert T, Sutton M St John, Weber KT. Anatomic validation of left ventricular mass estimates from clinical two-dimensional echocardiography: initial research. Circulation 1983;67:348-52.
20. Lowes BD, Gill EA, Rodriguez-Larrain, Abraham WT, Bristow MR, Gilbert EM. Carvedilol is associated with a reversal of remodeling in chronic heart failure [abstract]. Circulation 1996;94(suppl):I407.
21. Marino P, Zanolla L, Zaerdini P. Effect of streptokinase on left ventricular modelling and function after myocardial infarction: the GISSI (Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico) Trial. J Am Coll Cardiol 1989;14:1149-58.
22. Vaughan D, Lamas G, Pfeffer MA. Role of left ventricular dysfunction in selective neurohormonal activation in the recovery phase of anterior wall acute myocardial infarction. Am J Cardiol 1990;66:529-32.
23. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Circulation 1990;81:1161-72.
24. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N. Engl J Med 1992;327:669-77.
25. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985;57:84-95.
26. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 1988;319:80-6.
27. Peter T, Norris RM, Clarke ED. Reduction of enzyme levels by propranolol afteracute myocardial infarction. Circulation 1978;57:1091-5.
28. Yusuf S, Sleight P, Rossi P, et al. Reduction in infarct size, arrhythmias and chest pain by early intravenous beta blockade in suspected acute myocardial infarction. Circulation 1983;67:I32-41.
29. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. N Engl J Med 1989;320:618-27.
30. Brener SJ, Cox, JL, Pfisterer ME, Armstrong PW, Califf RM, Topol EJ. The potential for unexpected hazard of intravenous beta-blockade for acute myocardial infarction: results from the GUSTO trial [abstract]. J Am Coll Cardiol Feb 1995;25:5A.
31. The MIAMI Trial Research Group: metoprolol in acute myocardial infarction (MIAMI). A randomized placebo-controlled international trial. Eur Heart J 1985;6:199-26.
32. ISIS-1 (First International Study of Infarct Survival) Collaborative Group Randomized trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction. ISIS-1. Lancet 1986;2:57-66.
33. Yusuf S, Petro R, Lewis J, Sleight P. Beta blockade during and after myocardial infarction; an overview of the randomized trials. Prog Cardiovasc Dis 1985;17:335-71.
34. Erbel R, Schweizer P, Krebs W, Langen H, Meyer J, Effert S. Effects of heart rate changes on left ventricular volume and ejection fraction: a 2-dimensional echocardiographic study. Am J Cardiol 1984;53:590-7.
35. Sackner-Bernstein JD, Manani DM. Rationale for treatment of patients with chronic heart failure with adrenegic blockade. JAMA 1995;274:1462-7.
36. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Left ventricular remodeling with carvedilol in patients with congestivee heart failure due to ischemic heart disease. J Am Coll Cardiol 1997;29;1060-6.